Literature DB >> 24793618

Investigation of the hepatotoxicity of flutamide: pro-survival/apoptotic and necrotic switch in primary rat hepatocytes characterized by metabolic and transcriptomic profiles in microfluidic liver biochips.

Audrey Legendre1, Sébastien Jacques2, Florent Dumont2, Jérôme Cotton3, Patrick Paullier1, Marie José Fleury1, Eric Leclerc4.   

Abstract

We investigated the effects of the liver damage induced by flutamide in primary rat hepatocytes using liver microfluidic biochips. Flutamide is a non-steroidal anti-androgenic drug. Two flutamide concentrations, 10 μM and 100 μM, were used to expose the hepatocytes for 24h under perfusion. Thanks to the maintenance of hepatocyte differentiation phenotype and to the biotransformation performance in the microfluidic cultures, the metabolic ratio analysis of hydroxyflutamide, flutamide-gluthatione and hydroxyflutamide-gluthatione productions demonstrated saturation of the drug's biotransformation process and the maintenance of a high level of flutamide at 100 μM when compared to 10 μM. A microarray analysis comparing flutamide (10 or 100 μM) with controls revealed a common response for both concentrations illustrated by modulating the expression of the mRNA of genes associated with mitochondrial perturbation, of the proliferator-activated receptors (Ppar) signaling, lipid and fatty acid metabolism, antioxidant defense, and cell death pathways, consistently with in vitro and in vivo reports. Additionally to literature reports, our integration of the transcriptomic profiles demonstrated a specific dose dependent response. We found at 10 μM a typical pro-survival/apoptosis network activation (through IGF/PDGFD upstream route and via a downstream up regulation in CREB5, BCL2, IKBKG routes in the PI3K/signaling). We also found a down regulation of mRNA levels in sugar and amino acid metabolism pathways. At 100 μM a typical necrosis switch was observed associated with a down regulation of the tight junctions' pathway, a cellular aggregation and a reduction of the cell viability. Altogether our data demonstrated the potential and the sensitivity of our liver microfluidic cultures to evaluate xenobiotic toxicity by improving in vitro analysis and reproducing both in vitro and in vivo results. Finally, we proposed two integrated synthetic networks to describe the response of rat hepatocytes to both exposure concentrations of flutamide.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Flutamide; Hepatotoxicity; Metabolism; Microarray; Microfluidic biochips; Rat primary hepatocytes; Transcriptomic

Mesh:

Substances:

Year:  2014        PMID: 24793618     DOI: 10.1016/j.tiv.2014.04.008

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  3 in total

Review 1.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Authors:  Uwe Marx; Tommy B Andersson; Anthony Bahinski; Mario Beilmann; Sonja Beken; Flemming R Cassee; Murat Cirit; Mardas Daneshian; Susan Fitzpatrick; Olivier Frey; Claudia Gaertner; Christoph Giese; Linda Griffith; Thomas Hartung; Minne B Heringa; Julia Hoeng; Wim H de Jong; Hajime Kojima; Jochen Kuehnl; Marcel Leist; Andreas Luch; Ilka Maschmeyer; Dmitry Sakharov; Adrienne J A M Sips; Thomas Steger-Hartmann; Danilo A Tagle; Alexander Tonevitsky; Tewes Tralau; Sergej Tsyb; Anja van de Stolpe; Rob Vandebriel; Paul Vulto; Jufeng Wang; Joachim Wiest; Marleen Rodenburg; Adrian Roth
Journal:  ALTEX       Date:  2016-05-15       Impact factor: 6.043

Review 2.  Microfluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering.

Authors:  Ana Rubina Perestrelo; Ana C P Águas; Alberto Rainer; Giancarlo Forte
Journal:  Sensors (Basel)       Date:  2015-12-10       Impact factor: 3.576

3.  Integrated expression profiles of mRNA and microRNA in the liver of Fructus Meliae Toosendan water extract injured mice.

Authors:  Jie Zheng; Cai Ji; Xiaoyan Lu; Wei Tong; Xiaohui Fan; Yue Gao
Journal:  Front Pharmacol       Date:  2015-10-19       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.